

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspal642cxy

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 BELISTIN: Reload and Implementation of a New Subject Area
NEWS 4 ZDB will be removed from STN
NEWS 5 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Federal Research in Progress (FEDRIP) now available
NEWS 9 New e-mail delivery for search results now available
NEWS 10 MEDLINE Reload
NEWS 11 PCTFUL has been reloaded
NEWS 12 FORGE no longer contains STANDARDS file segment
NEWS 13 USAN to be reloaded July 28, 2002:
saved answer sets no longer valid
NETFIRST to be removed from STN
NEWS 14 Enhanced polymer searching in REGISTRY
NEWS 15 CANCERLIT reloaded
NEWS 16 PHARMARKETLIT(PHARMATL) - new on STN
NEWS 17 NTIS has been reloaded and enhanced
NEWS 18 Aquatic Toxicity Information Retrieval (AQUIRE)
NEWS 19 now available on STN
NEWS 20 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Sequence searching in REGISTRY enhanced
NEWS 23 JAPLO has been reloaded and enhanced
NEWS 24 Experimental properties added to the REGISTRY file
NEWS 25 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 EVENTLINE has been reloaded
NEWS 28 BELISTIN adds new search fields
NEWS 29 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30 MEDLINE SDI run of October 8, 2002
NEWS 31 DRILIT has been renamed APOLLIT
NEWS 32 More calculated properties added to REGISTRY
NEWS 33 TIBKAT will be removed from STN
NEWS 34 CSA files on STN
NEWS 35 PCTFUL now covers WP/PCT Applications from 1978 to date
NEWS 36 TOXCENTER enhanced with additional content
NEWS 37 Adis Clinical Trials Insight now available on STN
NEWS 38 ISMEC no longer available
NEWS 39 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40 NUTRACEUT offering one free connect hour in February 2003
NEWS 41 PHARMATL offering one free connect hour in February 2003
NEWS 42 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC
NEWS 43 CANCERLIT is no longer being updated
NEWS 44 METADEX enhancements
NEWS 45 PCTGEN now available on STN
NEWS 46 TEMA now available on STN

NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 48 Feb 26 PCTFUL now contains images
NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0b(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 17:51:31 ON 11 MAR 2003

=> file medline, cancerlit, biosis, confsci, embase, caplus, scisearch, uspatfull,
pctfull
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FILE ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 17:52:19 ON 11 MAR 2003

FILE 'CANCERLIT' ENTERED AT 17:52:19 ON 11 MAR 2003

FILE 'BIOSIS' ENTERED AT 17:52:19 ON 11 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CONFSCI' ENTERED AT 17:52:19 ON 11 MAR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'EMBASE' ENTERED AT 17:52:19 ON 11 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 17:52:19 ON 11 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 17:52:19 ON 11 MAR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'USPATFULL' ENTERED AT 17:52:19 ON 11 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFUL' ENTERED AT 17:52:19 ON 11 MAR 2003
COPYRIGHT (C) 2003 Univentio

=> s phospholipase (5a) inhibitor?
11 20025 PHOSPHOLIPASE (5A) INHIBITOR?

=> s 11 and cancer? or neoplasia?
 L2 138363 L1 AND CANCER? OR NEOPLASIA?
 L3 => s 11 and adenocarcinoma?
 178 L1 AND ADENOCARCINOMA?
 => dup rem 13
 PROCESSING COMPLETED FOR L3
 L4 139 DUP REM L3 (39 DUPLICATES REMOVED)
 => s 14 and pla2
 13 L4 AND PLA2
 => d 1-13
 L5 ANSWER 1 OF 13 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 AN 1988:575393 BIOSIS
 DN BAE6:59303
 TI EXPRESSION OF A UTEROGLIOMIN-LIKE PROTEIN IN HUMAN PROSTATE.
 AU MANYAK M J; KIKUKAWA T; MUKHERJEE A B
 CS RADIATION ONCOL. BRANCH, EXPERIMENTAL, PHOTOTHERAPY SECT., BUILD. 10, ROOM
 B3-B69, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892.
 SO J UROL. (1988) 140 (1), 176-182.
 FS BA; OLD
 ENGLISH
 L5 ANSWER 2 OF 13 USPTFULL
 AN 2002:75239 USPTFULL
 TI Isolated human phospholipase proteins, nucleic acid molecules encoding
 human phospholipase proteins, and uses thereof
 Beasley, Ellen M, Darnestown, MD, United States
 Van, Chunhua, Boyds, MD, United States
 Di Francesco, Valentina, Rockville, MD, United States
 PE Corporation (NY), Norwalk, CT, United States (U.S. corporation)
 PI US 6358842 B1 20020409 (9)
 AI US 2001-801052 B1 20010308 (9)
 PRAI US 2000-25386P 20001215 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2648
 INCL INCLM: 435/198.000
 INCLS: 435/252.300; 435/320.100; 435/243.000; 435/252.100; 536/023.100;
 536/023.200
 NCLM: 435/198.000
 NCLS: 435/243.000; 435/252.100; 435/252.300; 435/320.100; 536/023.100;
 536/023.200
 IC (7)
 ICM: C12N009-20
 ICS: C12N001-20; C12N015-00; C07H021-04
 EXP 435/198; 435/252.3; 435/243; 435/252.1; 435/320.1; 536/23.2; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 3 OF 13 USPTFULL
 AN 1999:92577 USPTFULL
 TI Use of uteroglobin expression as a molecular marker for prostatic
 intraepithelial neoplasia
 Paterino, Steven R., Falls Church, VA, United States
 Manyak, Michael J., Chevy Chase, MD, United States
 PA The George Washington University, Washington, DC, United States (U.S.
 corporation)
 PI US 5935860 19990810
 AI US 1996-658796 19960605 (8)
 RLI Continuation-in-part of Ser. No. US 1995-486203, filed on 7 Jun 1995
 which is a continuation-in-part of Ser. No. US 1995-400084, filed on 7

Mar 1995, now patented, Pat. No. US 5696092
 DT Utility
 FS Granted
 LN.CNT 2226
 INCL INCLM: 436/054.000
 INCLS: 600/564.000
 NCLM: 436/054.000
 NCLS: 600/564.000
 IC (6)
 ICM: G01N033-48
 EXP 436/54; 600/564
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 4 OF 13 USPTFULL
 AN 96:27184 USPTFULL
 TI PMA-sub.2 inhibitors and their use for inhibition of intestinal
 cholesterol absorption
 Homan, Reynold, Ann Arbor, MI, United States
 PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S.
 corporation)
 PI US 5504073 19960402
 AI US 1994-269746 19940701 (8)
 DT Utility
 FS Granted
 LN.CNT 960
 INCL INCLM: 514/130.000
 INCLS: 514/113.000; 514/128.000; 558/197.000
 NCLM: 514/130.000
 NCLS: 514/113.000; 514/128.000; 558/197.000
 IC (6)
 ICM: A61K031-66
 EXP 558/197; 514/130; 514/113; 514/128
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 5 OF 13 PCTFULL COPYRIGHT 2003 Univentio
 AN 2003000111 PCTFULL ED 20030115 EV 200301
 TI HUMAN (UTEROGLIOMIN-RELATED PROTEIN) 1 PROMOTER AND ITS USE
 PROMOTEUR DE L' (PROTEINE LIEE A L'UTEROGLIOMINE) 1 HOMALINE ET SON
 UTILISATION
 IN KIMURA, Shoko, 5 Dudley Court, Bethesda, MD 20814, US [JP, US];
 NIMI, Tomaki, 4710 Bethesda Avenue, Apartment #912, Bethesda, MD
 20814, US [JP, US]
 PA THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE
 SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, The National
 Institutes of Health, Office of Technology Transfer, 6001 Executive
 Boulevard, Suite #25, Rockville, MD 20852-3804, US [US, US], for all
 designates States except US;
 KIMURA, Shoko, 5 Dudley Court, Bethesda, MD 20814, US [JP, US], for US
 only;
 NIMI, Tomaki, 4710 Bethesda Avenue, Apartment #912, Bethesda, MD
 20814, US [JP, US], for US only
 NOONAN, William, D., Klarquist, Sparkman, LLP, One World Trade Center,
 Suite 1600, 121 S.W. Salmon Street, Portland, OR 97204, US
 LAF English
 LA Patent
 DT Patent
 DS WO 2003000111 A2 20030103
 W: AE AG AL AM AT AU BA BB BG BR BY BZ CA CH CN CO CR CU CZ
 DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
 KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MN MM MX MY
 NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TN TR TT TZ
 UA UG US UZ VN VU YU ZA ZW ZY
 RW (ARIPO): CH GM KE LS MW MZ SZ TZ UG ZW ZY
 RW (BAP): AM AZ BY KG KZ MD RU TJ TM
 RW (BPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

AI (OARI): BF BJ CF CG CI CM CA CN GQ GW ML MR NE SN TD TG
 WO 2002-0519456 A 20020620
 US 2001-60/299, 828 20010620
 PRAI

ANSWER 6 OF 13 PCTFULL. COPYRIGHT 2003 Univentio
 2002031162 PCTFULL. ED 20020515. EW 200216
 REGULATION OF HUMAN PHOSPHOLIPASE A2-LIKE ENZYME
 TIER REGULATION OF HUMAN PHOSPHOLIPASE A2-LIKE ENZYME
 TIFR ZHU, Zhimin, 45 Hincley Road, Waban, MA 02468, US [CN, US]
 IN BAYER AKTIENGESellschaft, 51368 Leverkusen, DE [DE, DE], for all
 PA designates States except US;
 ZHU, Zhimin, 45 Hincley Road, Waban, MA 02468, US [CN, US], for US only
 AG BAYER AKTIENGESellschaft, 51368 Leverkusen, DE
 LAF English
 LA Patent
 DT WO 2002031162 A2 20020418
 PI

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ
 DE DK DM DZ EC EE ES FI GB GD GE GH GM GR HU ID IL IN IS JP
 KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MX MY
 NO NZ PH PL PT RO RU SD SE SG SI SK SL SJ ST SV SW SY SZ TD TG
 US UZ VN YU ZA ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
 RW (EPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OARI): BF BJ CF CG CI CM CA CN GQ GW ML MR NE SN TD TG
 WO 2001-EP11642 A 20011009
 US 2000-60/238, 434 20001010
 US 2000-60/258, 051 20001227
 US 2001-60/315, 982 20010831
 ICM C12N015-55
 C12N015-62; C12N015-11; C12N009-20; C12N005-10; C12N001-19;
 C12N001-68; C12Q001-02; A61K039-395; A61K048-00; G01N033-68;
 G01N033-573
 ICS

ANSWER 7 OF 13 PCTFULL. COPYRIGHT 2003 Univentio
 2002031161 PCTFULL. ED 20020515. EW 200216
 REGULATION OF HUMAN PHOSPHOLIPASE-LIKE ENZYME
 TIER REGULATION OF HUMAN PHOSPHOLIPASE-LIKE ENZYME
 TIFR ZHU, Zhimin, 45 Hincley Road, Waban, MA 02468, US [CN, US]
 IN BAYER AKTIENGESellschaft, 51368 Leverkusen, DE [DE, DE], for all
 PA designates States except US;
 ZHU, Zhimin, 45 Hincley Road, Waban, MA 02468, US [CN, US], for US only
 AG BAYER AKTIENGESellschaft, 51368 Leverkusen, DE
 LAF English
 LA Patent
 DT WO 2002031161 A2 20020418
 PI

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ
 DE DK DM DZ EC EE ES FI GB GD GE GH GM GR HU ID IL IN IS JP
 KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MX MY
 NO NZ PH PL PT RO RU SD SE SG SI SK SL SJ ST SV SW SY SZ TD TG
 US UZ VN YU ZA ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
 RW (EPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OARI): BF BJ CF CG CI CM CA CN GQ GW ML MR NE SN TD TG
 WO 2001-EP11641 A 20011009
 US 2000-60/238, 445 20001010
 US 2000-60/257, 293 20001226
 ICM C12N015-55
 C12N015-62; C12N009-20; C07K016-40; C12Q001-68; G01N033-50;
 A61K031-7088; A61K038-46
 ICS

ANSWER 8 OF 13 PCTFULL. COPYRIGHT 2003 Univentio

AN 2002031160 PCTFULL. ED 20020515. EW 200216
 TIER REGULATION OF HUMAN PHOSPHOLIPASE A2-LIKE ENZYME
 TIFR REGULATION OF HUMAN PHOSPHOLIPASE A2-LIKE ENZYME
 IN ZHU, Zhimin, 45 Hincley Road, Waban, MA 02468, US [CN, US]
 PA BAYER AKTIENGESellschaft, 51368 Leverkusen, DE [DE, DE], for all
 AG designates States except US;
 ZHU, Zhimin, 45 Hincley Road, Waban, MA 02468, US [CN, US], for US only
 LAF BAYER AKTIENGESellschaft, 51368 Leverkusen, DE
 LA English
 DT Patent
 PI WO 2002031160 A2 20020418

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ
 DE DK DM DZ EC EE ES FI GB GD GE GH GM GR HU ID IL IN IS JP
 KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MX MY
 NO NZ PH PL PT RO RU SD SE SG SI SK SL SJ ST SV SW SY SZ TD TG
 US UZ VN YU ZA ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
 RW (EPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OARI): BF BJ CF CG CI CM CA CN GQ GW ML MR NE SN TD TG
 WO 2001-EP11640 A 20011009
 US 2000-60/238, 432 20001010
 US 2000-60/258, 053 20001227
 US 2001-60/317, 964 20010910
 ICM C12N015-55
 C12N015-63; C12N015-62; C12N001-21; C12N005-10;
 C12Q001-44; C12Q001-68; G01N033-68
 ICS

ANSWER 9 OF 13 PCTFULL. COPYRIGHT 2003 Univentio
 2002031125 PCTFULL. ED 20020515. EW 200216
 REGULATION OF HUMAN PHOSPHOLIPASE A2-LIKE ENZYME
 TIER REGULATION OF HUMAN PHOSPHOLIPASE A2-LIKE ENZYME
 TIFR ZHU, Zhimin, 45 Hincley Road, Waban, MA 02468, US [CN, US]
 IN BAYER AKTIENGESellschaft, 51368 Leverkusen, DE [DE, DE], for all
 PA designates States except US;
 ZHU, Zhimin, 45 Hincley Road, Waban, MA 02468, US [CN, US], for US only
 AG BAYER AKTIENGESellschaft, 51368 Leverkusen, DE
 LAF English
 LA Patent
 DT WO 2002031125 A2 20020418
 PI

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ
 DE DK DM DZ EC EE ES FI GB GD GE GH GM GR HU ID IL IN IS JP
 KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MX MY
 NO NZ PH PL PT RO RU SD SE SG SI SK SL SJ ST SV SW SY SZ TD TG
 US UZ VN YU ZA ZW
 RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW
 RW (EPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
 RW (OARI): BF BJ CF CG CI CM CA CN GQ GW ML MR NE SN TD TG
 WO 2001-EP11703 A 20011010
 US 2000-60/238, 433 20001010
 US 2000-60/258, 052 20001227
 ICM C12N009-00

ANSWER 10 OF 13 PCTFULL. COPYRIGHT 2003 Univentio
 200102676 PCTFULL. ED 20020620
 METHODS OF TREATING OR PREVENTING CELL, TISSUE, AND ORGAN DAMAGE USING
 HUMAN MELOID PROGENITOR INHIBITORY FACTOR-1 (MP1F-1)
 TIFR METHODES DE TRAITEMENT OU DE PREVENTION DE LIONS DES CELLULES, DES
 TISSUS ET DES ORGANES UTILISANT LE FACTEUR-1 INHIBITEUR DES PRECURSEURS
 MELOIDES (MP1F-1) D'ORIGINE HUMAINE
 IN GREGORZESKI, Krzysztof, J.;
 ROSEN, Craig, A.;

TI Amino-alcohol substituted cyclic compounds
IN Kumar, Anil M., Seattle, WA, United States
Michnick, John, Seattle, WA, United States
Underiner, Gail E., Briar, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5837703 19981117
AI US 1993-152650 19931112 (8)
RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
now abandoned
DT Utility
FS Granted
LN CNT 2596
INCL INCLM: 514/183.000
INCLS: 514/211.000; 514/228.800; 514/241.000; 514/242.000; 514/249.000;
514/256.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000;
514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;
514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;
540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;
544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;
546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;
548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000
NCLM: 514/183.000
NCLS: 514/211.150; 514/228.800; 514/241.000; 514/242.000; 514/249.000;
514/256.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000;
514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;
514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;
540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;
544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;
546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;
548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000
IC [6]
ICM: A61K031-55
ICS: A61K031-51.5; A61K031-44.5; A61K031-52
EXF 544/276; 544/272; 544/216; 544/257; 544/285; 544/286; 544/301; 544/311;
544/335; 514/263; 514/183; 514/211; 514/228.8; 514/241; 514/242;
514/249; 514/256; 514/259; 514/270; 514/274; 514/309; 514/312; 514/315;
514/348; 514/357; 514/374; 514/400; 514/418; 514/425; 514/427; 540/467;
540/544; 546/96; 546/141; 546/142; 546/157; 546/246; 546/296; 546/334;
548/215; 548/340.1; 548/485; 548/546; 548/561
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 42 USPTAFULL
LN 1998-134796
TI Determining invasiveness of prostatic adenocarcinoma
IN Pacterino, Steven R., Falls Church, VA, United States
PA Manyak, Michael, Chevy Chase, MD, United States
George Washington University, Washington, DC, United States (U.S. corporation)
PI US 5830640 19981103
AI US 1995-486203 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-400084, filed on 7 Mar 1995
DT Utility
FS Granted
LN CNT 2164
INCL INCLM: 435/004.000
INCLS: 435/007.100; 435/040.500; 435/040.520; 530/386.000; 530/387.100;
NCLM: 435/004.000
NCLS: 435/007.100; 435/040.500; 435/040.520; 530/386.000; 530/387.100;
530/387.900
IC [6]
ICM: C120001-00
ICS: G01N033-53; C07K016-00

EXF 424/94.1; 424/184.1; 424/277.1; 536/23.1; 435/6; 435/7.1; 435/4;
435/40.5; 435/40.52; 530/386; 530/387.1; 530/387.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 42 USPTAFULL
LN 1998-111942
TI Therapeutic compounds containing pyrimidinyl moieties
IN Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Briar, WA, United States
Underiner, Gail E., Briar, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5807862 19980915
AI US 1995-478112 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,
now abandoned
DT Utility
FS Granted
LN CNT 2190
INCL INCLM: 514/269.000
INCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000
NCLM: 514/269.000
NCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000
IC [6]
ICM: A61K031-505
ICS: C07D239-54
EXF 514/269; 514/274; 544/309; 544/310; 544/311; 544/312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 42 USPTAFULL
LN 1998-104751
TI Amino alcohol substituted cyclic compounds
IN Michnick, John, Seattle, WA, United States
Underiner, Gail E., Briar, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5801181 19980901
AI US 1995-474820 19950607 (8)
RLI Division of Ser. No. US 1993-152650, filed on 12 Nov 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31
Mar 1993
DT Utility
FS Granted
LN CNT 2822
INCL INCLM: 514/263.000
INCLS: 514/183.000; 514/249.000; 514/259.000; 514/274.000; 514/309.000;
514/315.000; 514/418.000; 514/425.000; 514/425.000; 514/617.000; 514/619.000;
514/626.000; 514/668.000; 514/669.000
NCLM: 514/263.350
NCLS: 514/183.000; 514/249.000; 514/259.000; 514/274.000; 514/309.000;
514/315.000; 514/418.000; 514/425.000; 514/425.000; 514/617.000; 514/619.000;
514/626.000; 514/668.000; 514/669.000
IC [6]
ICM: A01N043-00
ICS: A01N043-90; A01N043-58; A01N043-42
EXF 514/263; 514/249; 514/259; 514/265; 514/274; 514/309; 514/315; 514/418;
514/425; 514/617; 514/619; 514/626; 514/668; 514/669
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 42 USPTAFULL
LN 1998-98921
TI Oxohexyl methylxanthine compounds
IN Underiner, Gail, Briar, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5795897 19980818
 AI US 1994-227295 19940413 (8)
 RLI Continuation of Ser. No. US 1992-977993, filed on 18 Nov 1992
 DT Utility
 FS Granted
 LN CNT 592
 INCL INCLM: 514/261.000
 NCL INCLM: 514/885.000; 514/886.000
 NCLM: 514/211.070
 NCLS: 514/029.000; 514/171.000; 514/253.080; 514/254.070; 514/263.320;
 514/885.000; 514/886.000
 IC [6]
 ICM: A61K031-52
 EXF 514/261; 514/885
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 6 OF 42 USPTAFULL
 AN 1998:95545 USPTAFULL
 TI Enantiomerically pure hydroxylated xanthine compounds
 IN Woodson, James A., Seattle, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5792772 19980811
 AI US 1995-458957 19950601 (8)
 RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now patented,
 Pat. No. US 5652243 which is a division of Ser. No. US 1994-307554,
 filed on 16 Sep 1994, now patented, Pat. No. US 5648357 which is a
 continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
 abandoned which is a continuation-in-part of Ser. No. US 1992-926655,
 filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
 Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
 DT Utility
 FS Granted
 LN CNT 1734
 INCL INCLM: 514/263.000
 NCL INCLM: 514/263.360
 IC [6]
 ICM: A61K031-52
 EXF 514/263
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 7 OF 42 USPTAFULL
 AN 1998:79342 USPTAFULL
 TI Acetal- and ketal-substituted pyrimidine compounds
 IN Leigh, Alistair, Brier, WA, United States
 Underiner, Gail, Brier, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5777115 19980707
 AI US 1994-193331 19940207 (8)
 RLI Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now
 abandoned
 DT Utility
 FS Granted
 LN CNT 1632
 INCL INCLM: 544/242.000
 NCL INCLM: 544/267.000; 514/269.000; 514/270.000; 514/256.000
 NCLM: 544/242.000
 NCLS: 544/267.000
 IC [6]
 ICM: C07D239-26
 EXF 544/267; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 42 USPTAFULL
 AN 1998:72620 USPTAFULL
 TI Oxime substituted therapeutic compounds
 IN Klein, J. Peter, Washon, WA, United States
 Leigh, Alistair, Brier, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5770595 19980623
 AI US 1994-193344 19940207 (8)
 RLI Continuation of Ser. No. US 1993-6083, filed on 19 Jan 1993, now
 abandoned
 DT Utility
 FS Granted
 LN CNT 2183
 INCL INCLM: 514/263.000
 NCL INCLM: 544/271.000; 544/273.000
 NCLM: 514/263.360
 NCLS: 514/151.000; 544/271.000; 544/273.000
 IC [6]
 ICM: M61K031-52
 EXF 514/263; 544/271; 544/273
 L9 ANSWER 9 OF 42 USPTAFULL
 AN 1998:39529 USPTAFULL
 TI Enantiomerically pure hydroxylated xanthine compounds to treat
 IN Woodson, James A., Seattle, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5739138 19980414
 AI US 1995-457703 19950601 (8)
 RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned
 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994,
 now abandoned which is a continuation of Ser. No. US 1993-13977, filed
 on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No.
 US 1992-926655, filed on 7 Aug 1992, now abandoned which is a
 continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992,
 now abandoned
 DT Utility
 FS Granted
 LN CNT 1734
 INCL INCLM: 514/263.000
 NCL INCLM: 514/263.360
 NCLM: 514/263.360
 NCLS: 514/866.000
 IC [6]
 ICM: A61K031-52
 EXF 514/263; 514/866
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L9 ANSWER 10 OF 42 USPTAFULL
 AN 97:86614 USPTAFULL
 TI Halogen, isothiocyanate or azide substituted xanthines
 IN Leigh, Alistair, Brier, WA, United States
 Michnick, John, Seattle, WA, United States
 Kumar, Anil, Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5670506 19970923
 AI US 1993-42946 19930405 (8)
 RLI Utility
 FS Granted
 LN CNT 1994

INCL INCLM: 514/258.000
 INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
 NCL NCLM: 514/141.000
 NCLS: 544/267.000; 544/272.000; 544/277.000
 IC [6]
 ICM: A61K031-52
 ICS: C07D073-00
 EXP 544/267; 544/276; 544/272; 544/277; 514/258
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 42 USPATFULT
 AN 97:66130 USPATFULT
 TI Methods of using enantiomerically pure hydroxylated xanthine compounds
 IN Bianco, James A., Seattle, WA, United States
 Singer, Jack, Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5652243810 19970729
 AI US 1994-343810 19941122 (8)
 RLI Division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation-in-part of Ser. No. US 1992-92665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
 DT Utility
 FS Granted
 LN CNT 1731
 INCL INCLM: 514/263.000
 INCLS: 514/262.000; 514/265.000; 514/814.000
 NCL NCLM: 514/263.360
 NCLS: 514/814.000
 IC [6]
 ICM: A61K031-52
 EXP 514/262; 514/263; 514/265
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 42 USPATFULT
 AN 97:61689 USPATFULT
 TI Enantiomerically pure hydroxylated xanthine compounds
 IN Bianco, James A., Seattle, WA, United States
 Woodson, Paul, Bothell, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5648357 19970715
 AI US 1994-307554 19940916 (8)
 RLI Continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-92665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
 DT Utility
 FS Granted
 LN CNT 1748
 INCL INCLM: 514/263.000
 INCLS: 514/267.000; 514/270.000; 514/271.000
 NCL NCLM: 514/263.360
 NCLS: 514/267.000; 514/270.000; 514/271.000
 IC [6]
 ICM: A61K031-52
 EXP 514/263; 514/267; 544/267; 544/270; 544/271
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 42 USPATFULT
 AN 97:54205 USPATFULT
 TI Regulation of x-ray mediated gene expression
 IN Weichselbaum, Ralph R., Chicago, IL, United States
 Hallahan, Dennis E., Park Ridge, IL, United States

PA Kufe, Donald W., Wellesley, MA, United States
 Arch Development Corp., Chicago, IL, United States (U.S. corporation)
 Dana-Farber Cancer Institute, Boston, MA, United States (U.S. corporation)
 PI US 5641755 19970624
 AI US 1994-278452 19940720 (8)
 RLI Continuation-in-part of Ser. No. US 1994-192107, filed on 4 Feb 1994, now abandoned
 DT Utility
 FS Granted
 LN CNT 1675
 INCL INCLM: 514/044.000
 INCLS: 424/009.200; 435/006.000; 435/029.000; 514/396.000; 935/036.000; 935/062.000; 536/024.100
 NCL NCLM: 514/044.000
 NCLS: 424/009.200; 435/006.000; 435/029.000; 514/396.000; 536/024.100
 IC [6]
 ICM: A61K048-00
 EXP 424/9.1; 424/1.11; 514/44; 514/396; 435/172.1; 435/172.3; 435/240.2; 435/6; 435/29; 536/24.1; 935/36; 935/62
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 42 USPATFULT
 AN 97:40793 USPATFULT
 TI Treatment of diseases using enantiomerically pure hydroxylated xanthine compounds
 IN Bianco, James A., Seattle, WA, United States
 Woodson, Paul, Bothell, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5629315 19970513
 AI US 1995-456900 19950601 (8)
 RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-92665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
 DT Utility
 FS Granted
 LN CNT 1736
 INCL INCLM: 514/263.000
 INCLS: 514/866.000
 NCL NCLM: 514/263.360
 NCLS: 514/866.000
 IC [6]
 ICM: A61K031-52
 EXP 514/263
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 42 USPATFULT
 AN 97:31820 USPATFULT
 TI Process for preparing enantiomerically pure xanthine derivatives
 IN Bianco, James A., Seattle, WA, United States
 Woodson, Paul, Bothell, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5621102 19970415
 AI US 1995-456897 19950601 (8)
 RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-92665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned

on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned

DT Utility
 FS Granted
 LN.CNT 1763
 INCL INCLM: 544/267.000
 INCLS: 514/340.000
 NCL NCLM: 544/267.000
 IC [6]
 ICM: C07D473-06
 ICS: C07D473-08; C07D473-12
 EXP 544/267
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 42 USPTFULT
 AN 97:31706 USPTFULT
 TI Enantiomerically pure hydroxylated xanthine compounds to treat inflammatory diseases
 IN Bianco, James A., Seattle, WA, United States
 Woodson, Paul, Bothell, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States
 PI US 5620984 19970415
 AI US 1995-456898 19950601 (8)
 RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned

DT Utility
 FS Granted
 LN.CNT 1721
 INCL INCLM: 514/263.000
 NCL NCLM: 514/263.360
 IC [6]
 ICM: A61K031-52
 EXP 514/263
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 42 USPTFULT
 AN 97:22792 USPTFULT
 TI Enantiomerically pure hydroxylated xanthine compounds to treat shock symptoms
 IN Bianco, James A., Seattle, WA, United States
 Woodson, Paul, Bothell, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5613349 19970318
 AI US 1995-457062 19950601 (8)
 RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned

DT Utility
 FS Granted
 LN.CNT 1725
 INCL INCLM: 514/263.000

NCL INCLS: 514/921.000
 NCLM: 514/263.360
 NCLS: 514/921.000
 IC [6]
 ICM: A61K031-52
 EXP 514/263
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 42 USPTFULT
 AN 96:116387 USPTFULT
 TI Modulation of cellular response to external stimuli
 IN Bianco, James A., Seattle, WA, United States
 Bursen, Stuart L., Snoqualmie, WA, United States
 Singer, Jack M., Seattle, WA, United States
 PA Fred Hutchinson Cancer Research Center, Seattle, WA, United States (U.S. corporation)
 PI US 5585380 19961217
 AI US 1995-378109 19950125 (8)
 RLI Continuation of Ser. No. US 1993-155361, filed on 22 Nov 1993, now abandoned which is a division of Ser. No. US 1992-888722, filed on 26 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-732227, filed on 16 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-704992, filed on 24 May 1991, now abandoned

DT Utility
 FS Granted
 LN.CNT 1461
 INCL INCLM: 514/263.000
 INCLS: 514/085.000; 514/247.000; 514/258.000
 NCL NCLM: 514/263.320
 NCLS: 514/085.000; 514/247.000; 514/263.310
 IC [6]
 ICM: A61K031-52
 ICS: A61K031-50
 EXP 514/85; 514/247; 514/252; 514/258; 514/263; 514/929
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 42 USPTFULT
 AN 96:111463 USPTFULT
 TI Enantiomerically pure hydroxylated xanthine compounds
 IN Bianco, James A., Seattle, WA, United States
 Woodson, Paul, Bothell, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5580874 19961203
 AI US 1995-457685 19950601 (8)
 RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned

DT Utility
 FS Granted
 LN.CNT 1733
 INCL INCLM: 514/263.000
 INCLS: 514/263.360
 NCL NCLM: 514/263.360
 IC [6]
 ICM: A61K031-52
 EXP 514/263
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 42 USPTFULT

AN 96:11462 USPTAFULL
 TI Enantiomerically pure hydroxylated xanthine compounds to treat
 IN Proliferative vascular diseases
 Bianco, James A., Seattle, WA, United States
 Woodson, Paul, Bothell, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States
 Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5580873
 US 1995-456899
 19950601 (8)
 Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a
 continuation of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a
 continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
 abandoned which is a continuation-in-part of Ser. No. US 1992-92665,
 filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
 Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
 DT Utility
 FS Granted
 LN CNT 1728
 INCL INCLM: 514/263.000
 NCL NCLM: 514/263.360
 IC [6]
 ICM: A61K031-52
 EXF 514/263
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 21 OF 42 USPTAFULL
 AN 96:97041 USPTAFULL
 TI R-enantiomerically pure hydroxylated xanthine compounds to treat baldness
 IN Bianco, James A., Seattle, WA, United States
 Woodson, Paul, Bothell, WA, United States
 Porubek, David, Edmonds, WA, United States
 Singer, Jack, Seattle, WA, United States
 Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5567704
 US 1995-457683
 19950601 (8)
 Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a
 continuation of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a
 continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now
 abandoned which is a continuation-in-part of Ser. No. US 1992-92665,
 filed on 7 Aug 1992, now abandoned which is a continuation-in-part of
 Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
 DT Utility
 FS Granted
 LN CNT 1736
 INCL INCLM: 514/263.000
 NCL NCLM: 514/263.360
 IC [6]
 ICM: A61K031-52
 EXF 514/263; 514/262
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 22 OF 42 USPTAFULL
 AN 96:46169 USPTAFULL
 TI Olefin substituted long chain compounds
 IN Underiner, Gail, Briar, WA, United States
 Porubek, David, Seattle, WA, United States
 Klein, J. Peter, Vashon, WA, United States
 Bissman, Eliza, Seattle, WA, United States
 Leigh, Alistair, Briar, WA, United States
 Kumar, Anil, Seattle, WA, United States
 Michnick, John, Seattle, WA, United States
 Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)

PI US 5521315
 AI US 1993-59697
 RLI Continuation-in-part of Ser. No. US 1993-3372, filed on 12 Jan 1993, now
 patented, Pat. No. US 5354756
 DT Utility
 FS Granted
 LN CNT 2761
 INCL INCLM: 546/243.000
 INCLM: 546/242.000; 544/285.000
 NCL NCLM: 546/243.000
 NCLM: 544/285.000; 546/242.000
 IC [6]
 ICM: C07D211-88
 ICS: C07D239-80
 EXF 548/545; 548/546; 548/547; 546/243; 544/285
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 23 OF 42 USPTAFULL
 AN 95:108287 USPTAFULL
 TI Substituted long chain alcohol xanthine compounds
 IN Underiner, Gail, Briar, WA, United States
 Porubek, David, Edmonds, WA, United States
 Klein, J. Peter, Vashon Island, WA, United States
 Woodson, Paul, Bothell, WA, United States
 Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5473070
 US 1992-976353
 19951205
 19921116 (7)
 DT Utility
 FS Granted
 LN CNT 890
 INCL INCLM: 544/267.000
 INCLM: 514/263.000
 NCL NCLM: 544/267.000
 IC [6]
 ICM: C07D473-04
 ICS: A61K031-52
 EXF 544/267; 514/263
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 24 OF 42 USPTAFULL
 AN 95:105868 USPTAFULL
 TI Cell signaling inhibitors
 IN Underiner, Gail E., Briar, WA, United States
 Klein, J. Peter, Vashon Island, WA, United States
 Rice, Glenn C., Seattle, WA, United States
 Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5470878
 US 1993-164081
 19931208 (8)
 Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,
 now abandoned
 DT Utility
 FS Granted
 LN CNT 2665
 INCL INCLM: 514/558.000
 INCLM: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000;
 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000;
 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000;
 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000;
 548/486.000; 548/556.000; 554/055.000; 554/061.000; 554/108.000;
 554/213.000; 560/130.000; 560/145.000; 562/553.000; 562/567.000;
 564/183.000; 564/197.000; 564/198.000; 564/201.000; 564/506.000
 NCL NCLM: 514/558.000
 NCLM: 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000;
 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000;

514/626.000; 514/629.000; 514/669.000; 544/254.000; 544/285.000;
544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000

IC [6]
ICM: A61K031-20
ICS: C07C233-00
EXF 554/51; 554/61; 554/55; 554/108; 554/213; 564/224; 564/506; 564/198;
564/215; 564/201; 564/197; 514/625; 514/629; 514/613; 514/558; 514/552;
514/529; 514/561; 514/626; 514/669; 560/130; 560/145; 562/553; 562/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 25 OF 42 USPTFULL.
AN 95:71491 USPTFULL.
TI Acetal or ketal substituted xanthine compounds
IN Leigh, Alisair, Edmonds, WA, United States
PA Underiner, Gail, Brler, WA, United States
PI Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
AI US 5440041 19950808
RUI US 1994-194135 19940208 (8)
Continuation of Ser. No. US 1993-4353, filed on 14 Jan 1993, now
abandoned
DT Utility
FS Granted
LN CNT 874
INCL INCLM: 544/267.000
NCLM: 544/268.000
NCLM: 544/267.000
NCLM: 544/268.000
IC [6]
ICM: C07D473-06
EXF 544/267; 544/268; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 26 OF 42 USPTFULL.
AN 94:88699 USPTFULL.
TI Olefin-substituted long chain xanthine compounds
IN Underiner, Gail, Brler, WA, United States
PA Porubek, David, Edmonds, WA, United States
PI Klein, J. Peter, Vashon Island, WA, United States
AI Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
AI US 5354756 19941011
AI US 1993-3372 19930112 (8)
DT Utility
FS Granted
LN CNT 846
INCL INCLM: 514/263.000
NCLM: 544/267.000; 544/272.000; 544/273.000
NCLM: 514/263.340
NCLM: 514/263.350; 514/263.360; 544/267.000; 544/272.000; 544/273.000
IC [5]
ICM: A61K031-52
ICS: C07D473-02
EXF 544/267; 544/272; 544/273; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 27 OF 42 USPTFULL.
AN 94:15745 USPTFULL.
TI Substituted epoxyalkyl xanthines
IN Klein, J. Peter, Vashon, WA, United States
PA Porubek, David, Edmonds, WA, United States
PI Rice, Glenn C., Seattle, WA, United States
AI Woodson, Paul, Bozell, WA, United States
AI Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
AI US 5288721 19940222
AI US 1992-949330 19920922 (7)
DT Utility

FS Granted
LN CNT 945
INCL INCLM: 514/263.000
NCLM: 544/267.000
NCLM: 514/263.230
NCLM: 514/263.320; 544/267.000
IC [5]
ICM: A61K031-52
ICS: C07D473-04
EXF 544/267; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 28 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
AN 199805319 PCTFULL. ED 20020514
TI GENE EXPRESSION PROFILES IN NORMAL AND CANCER CELLS
IN PROFILES D'EXPRESSION DE GENES DANS DES CELLULES NORMALES ET CANCEREUSES
PA VOGELSTEIN, Bert;
KINZLER, Kenneth, W.
THE JOHNS HOPKINS UNIVERSITY;
VOGELSTEIN, Bert;
KINZLER, Kenneth, W.
English
LA Patent
DT Patent
PI WO 9853319 A2 19981126
DS AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI
GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT
LU LV MD MG MN NM NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT UA UG US UZ VN YU ZW CH CY DE DK ES FI FR GB GR
AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR
IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD
TG

AI WO 1998-US10277 A 19980520
PRAI US 1997-60/047,352 19970521
ICM C120001-68
ICS G01N033-574

L9 ANSWER 29 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
AN 199803946 PCTFULL. ED 20020514
TI 70 HUMAN SECRETED PROTEINS
IN 70 PROTEINES HUMAINES SECRETEES
PA RUBEN, Steven, M.;
ROSEN, Craig, A.;
FISCHER, Carrie, L.;
SOOPET, Daniel, R.;
CARTER, Kenneth, C.;
BEDNARIK, Daniel, P.;
ENDRESS, Gregory, A.;
YU, Guo-Liang;
NI, Jian;
FENG, Ping;
YOUNG, Paul, E.;
GREENE, John, M.;
FERRIE, Ann, M.;
DUAN, Roxanne;
HU, Jing-Shan;
FLORENCE, Kimberley, A.;
OLSEN, Henrik, S.;
EBNER, Reinhard;
BREMER, Laurie, A.;
MOORE, Paul, A.;
SHI, Yangu;
LAFLEUR, David, W.;
LI, Yi;
ZENG, Zhizhen;
KYAM, Hia

PA HUMAN GENOME SCIENCES, INC.;

RUBEN, Steven, M.;

ROSEN, Craig, A.;

FISCHER, Carrie, L.;

SOPPET, Daniel, R.;

CHARTER, Kenneth, C.;

BEDNARIK, Daniel, F.;

ENDRESS, Gregory, A.;

YU, Guo-liang;

NI, Jian;

FENG, Ping;

YOUNG, Paul, E.;

GREENE, John, M.;

FERRIE, Ann, M.;

DUAN, Roxanne;

HU, Jing-Shan;

FLORENCE, Kimberley, A.;

OLSEN, Henrik, S.;

BEHNER, Reinhard;

BREMER, Laurie, A.;

MOORE, Paul, A.;

SHI, Yangu;

LAFLUR, David, W.;

LI, Yi;

ZENG, Zhichen;

KYAN, Hla

English

Patent

WO 9839446

LA A2 19980911

DT AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI

PI GB GE GH GM GN HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT

DS LU LV MD MG MN MO MX NO NZ PL PT RO RU SD SE SG SI SK SL

IT TM TR TT UA UG US UZ VN YU ZW GM KE LS MM SD SZ UG ZW

AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE

IT LU MC NL PT SE BF BJ CF CG CI CM CA GN ML MR NE SN TD TG

AI A 19980306

PRAI WO 1998-US4482

US 1997-60/040, 162 19970307

US 1997-60/040, 333 19970307

US 1997-60/038, 621 19970307

US 1997-60/040, 161 19970307

US 1997-60/040, 626 19970307

US 1997-60/040, 334 19970307

US 1997-60/040, 336 19970307

US 1997-60/040, 163 19970307

US 1997-60/043, 580 19970411

US 1997-60/043, 568 19970411

US 1997-60/043, 516 19970411

US 1997-60/043, 569 19970411

US 1997-60/043, 311 19970411

US 1997-60/043, 671 19970411

US 1997-60/043, 674 19970411

US 1997-60/043, 669 19970411

US 1997-60/043, 312 19970411

US 1997-60/043, 313 19970411

US 1997-60/043, 672 19970411

US 1997-60/043, 315 19970411

US 1997-60/043, 578 19970411

US 1997-60/043, 576 19970411

US 1997-60/043, 670 19970411

US 1997-60/047, 598 19970523

US 1997-60/047, 632 19970523

US 1997-60/047, 503 19970523

US 1997-60/047, 613 19970523

US 1997-60/047, 600 19970523

US 1997-60/047, 615 19970523

US 1997-60/047, 583 19970523

US 1997-60/047, 617 19970523

US 1997-60/047, 502 19970523

US 1997-60/047, 592 19970523

US 1997-60/047, 581 19970523

US 1997-60/047, 584 19970523

US 1997-60/047, 587 19970523

US 1997-60/047, 580 19970523

US 1997-60/047, 492 19970523

US 1997-60/047, 597 19970523

US 1997-60/047, 618 19970523

US 1997-60/047, 582 19970523

US 1997-60/047, 596 19970523

US 1997-60/047, 612 19970523

US 1997-60/047, 633 19970523

US 1997-60/047, 601 19970523

US 1997-60/047, 595 19970523

US 1997-60/047, 599 19970523

US 1997-60/047, 588 19970523

US 1997-60/047, 585 19970523

US 1997-60/047, 586 19970523

US 1997-60/047, 590 19970523

US 1997-60/047, 594 19970523

US 1997-60/047, 589 19970523

US 1997-60/047, 593 19970523

US 1997-60/047, 614 19970523

US 1997-60/047, 501 19970523

US 1997-60/048, 964 19970606

US 1997-60/048, 974 19970822

US 1997-60/056, 886 19970822

US 1997-60/056, 887 19970822

US 1997-60/056, 889 19970822

US 1997-60/056, 893 19970822

US 1997-60/056, 630 19970822

US 1997-60/056, 878 19970822

US 1997-60/056, 662 19970822

US 1997-60/056, 872 19970822

US 1997-60/056, 882 19970822

US 1997-60/056, 637 19970822

US 1997-60/056, 903 19970822

US 1997-60/056, 888 19970822

US 1997-60/056, 879 19970822

US 1997-60/056, 880 19970822

US 1997-60/056, 894 19970822

US 1997-60/056, 911 19970822

US 1997-60/056, 636 19970822

US 1997-60/056, 874 19970822

US 1997-60/056, 910 19970822

US 1997-60/056, 864 19970822

US 1997-60/056, 631 19970822

US 1997-60/056, 845 19970822

US 1997-60/056, 892 19970822

US 1997-60/056, 632 19970822

US 1997-60/056, 664 19970822

US 1997-60/056, 876 19970822

US 1997-60/056, 881 19970822

US 1997-60/056, 909 19970822

US 1997-60/056, 875 19970822

US 1997-60/056, 862 19970822

US 1997-60/056, 887 19970822

US 1997-60/056, 908 19970822

US 1997-60/056, 884 19970822

US 1997-60/057, 761 19970905

US 1997-60/057, 650 19970905

ICM

C12N015-12

ICS C12N005-10; C12N001-21; C07K014-47; C07K016-18; C12Q001-66; G01N033-50; G01N033-53; G01N033-68; A61K038-17

L9 ANSWER 30 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
AN 1996041003 PCTFULL. ED 20020514
TIEN CORRECTAL CANCER RISK FACTOR DETECTION AND TREATMENT
TIIFR DETECTION DU FACTEUR DE RISQUE DU CANCER COLORECTAL ET TRAITEMENT
IN BUCHBERG, Arthur, M.;
BUCHBERG, Arthur, M.;
SIRACUSA, Linda, D.;
CHERENIK, Kenneth, P.;
THOMAS JEFFERSON UNIVERSITY;
PA BUCHBERG, Arthur, M.;
SIRACUSA, Linda, D.;
CHERENIK, Kenneth, P.;
LA English
PI Patent
DS WO 9641003 A1 19961219
DS W: 1996-US9009 A 19960606
PRAI US 1995-8/484,359 19950607
ICM C12Q001-68

L9 ANSWER 31 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
AN 1996040982 PCTFULL. ED 20020514
TIEN THERAPEUTIC INHIBITION OF PHOSPHOLIPASE A2 IN NEURODEGENERATIVE DISEASE
TIIFR INHIBITION THERAPEUTIQUE DE LA PHOSPHOLIPASE A2 DANS UNE MALADIE NEURO-DEGENERATIVE
IN RYDEL, Russell, E.;
DAPPEN, Michael, S.;
JOHN, Varghese;
FANG, Lawrence, Yung-Sun;
THORSETT, Eugene, D.;
ATHENA NEUROSCIENCES, INC.;
PA RYDEL, Russell, E.;
DAPPEN, Michael, S.;
JOHN, Varghese;
FANG, Lawrence, Yung-Sun;
THORSETT, Eugene, D.;
LA English
PI Patent
DS WO 9640982 A1 19961219
DS W: 1996-US9772 A 19960607
PRAI US 1995-8/476,464 19950607
US 1995-8/476,463 19950607
ICM C12Q001-34 19950607
ICS C12Q001-00; A61K031-63

L9 ANSWER 32 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
AN 1996040657 PCTFULL. ED 20020514
TIEN INHIBITORS OF PHOSPHOLIPASE A2
TIIFR INHIBITEURS DE LA PHOSPHOLIPASE A2
IN PATTERNO, Stephen, R.;
MANTAK, Michael, J.;
PA THE GEORGE WASHINGTON UNIVERSITY
LA English
PI Patent
DS WO 9640657 A1 19961219
DS W: 1996-US9772 A 19960607
PRAI US 1995-8/476,464 19950607
US 1995-8/476,463 19950607
ICM C12Q001-34 19950607
ICS C12Q001-00; A61K031-63

AI WO 1996-US10221 A 19960606
PRAI US 1995-8/486,203 19950607
ICS C12N005-08; A61K031-41

L9 ANSWER 33 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
AN 1996025947 PCTFULL. ED 20020514
TIEN INDUCTION OF E-SELECTIN FOR TARGETTING THERAPEUTIC AGENTS
TIIFR INDUCTION DE SELECTINE E POUR AGENTS DE CIBLAGE THERAPEUTIQUES
IN WETSSELBAUM, Ralph, R.;
ARCH DEVELOPMENT CORPORATION;
PA HALAHAN, Dennis, E.;
WETSSELBAUM, Ralph, R.;
LA English
PI Patent
DS WO 9625947 A2 19960829
DS W: 1996-US7796 A 19960221
PRAI US 1995-8/392,541 19950221
ICM A61K041-00 19950221
ICS A61K051-10; A61K051-12; A61K048-00; A61K047-48

L9 ANSWER 34 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
AN 1995022546 PCTFULL. ED 20020514
TIEN INTRACELLULAR SIGNALING MEDIATORS
TIIFR MEDIATEURS DE SIGNALISATION INTRACELLULAIRE
IN KLEIN, U., Peter;
LEIGH, Alistair, J.;
UNDERLINER, Gail, E.;
KUMAR, Anil;
RICE, Glenn, C.;
CELL THERAPEUTICS, INC.
PA English
PI Patent
DS WO 9522546 A1 19950824
DS W: 1995-US2122 A 19950217
PRAI US 1994-8/199,368 19940218
ICS A61K031-52; A61K031-505

L9 ANSWER 35 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
AN 1994024133 PCTFULL. ED 20020513
TIEN RING-SUBSTITUTED CELL SIGNALING INHIBITORS
TIIFR INHIBITEURS DE SIGNALISATION CELLULAIRE A CYCLE SUBSTITUE
IN KLEIN, J., Peter;
KUMAR, Anil;
LEIGH, Alistair;
MICHEWICK, John;
RICE, Glenn, C.;
CELL THERAPEUTICS, INC.
PA English
PI Patent
DS WO 9424133 A1 19941027
DS W: 1994-US4007 A 19940411
DS W: 1994-US4007 A 19940411

PRAI US 1993-8/045, 399 19930409
 US 1994-8/192, 321 19940203
 ICS A61K031-52; A61K031-445; A61K031-40; A61K031-505
 L9 ANSWER 36 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
 AN 1994016704 PCTFULL. ED 20020513
 TIEN OXIME-SUBSTITUTED THERAPEUTIC COMPOUNDS
 TIFR COMPOSES THERAPEUTIQUES A SUBSTITUTION OXIME
 IN LEIGH, Alistair;
 PA KLEIN, J., Peter
 CELL THERAPEUTICS, INC.
 LA English
 DT Patent
 PI WO 9416704 A1 19940804
 DS W: AU CA JP NZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 AI WO 1994-US763 A 19940119
 PRAI US 1993-8/006, 083 19930119
 ICM A61K031-52
 L9 ANSWER 37 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
 AN 1994015605 PCTFULL. ED 20020513
 TIEN ACETAL OR KETAL SUBSTITUTED THERAPEUTIC COMPOUNDS
 TIFR COMPOSES THERAPEUTIQUES A SUBSTITUTION ACETAL OU CETAL
 IN LEIGH, Alistair;
 PA UNDERINER, Gall;
 CELL THERAPEUTICS, INC.
 LA English
 DT Patent
 PI WO 9415605 A1 19940721
 DS W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 AI WO 1994-US463 A 19940114
 PRAI US 1993-8/004, 353 19930114
 ICM A61K031-52
 L9 ANSWER 38 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
 AN 1994006431 PCTFULL. ED 20020513
 TIEN NOVEL EPOXIDE-CONTAINING COMPOUNDS
 TIFR NOUVEAUX COMPOSES EPOXY
 IN UNDERINER, Gall;
 KLEIN, J., Peter;
 MICHEINICK, John;
 LEIGH, Alistair;
 KUMAR, Anil
 CELL THERAPEUTICS, INC.
 LA English
 DT Patent
 PI WO 9406431 A1 19940331
 DS W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 AI WO 1993-US9073 A 19930922
 PRAI US 1992-7/949, 330 19920922
 ICM A61K031-52 US 1992-7/991, 655 19921216
 L9 ANSWER 39 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
 AN 1993017684 PCTFULL. ED 20020513
 TIEN ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS
 TIFR COMPOSES A BASE DE XANTHINE HYDROXYLEE ENANTIOMERE
 IN BIANCO, James, A.;
 WOODSON, Paul;
 PORUBER, David;
 SINGER, Jack
 CELL THERAPEUTICS, INC.
 LA English
 DT Patent
 PI WO 9317684 A2 19930916

DS W: AU BR CA FI HU JP KR NO RU UA AT BE CH DE DK ES FR GB GR IE
 IT LU MC NL PT SE
 AI WO 1993-US2104 A 19930301
 PRAI US 1992-7/846, 354 19920304
 ICM US 1992-7/926, 665 19920807
 A61K031-44
 L9 ANSWER 40 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
 AN 1993004079 PCTFULL. ED 20020513
 TIEN METHOD FOR GENERATING AND SCREENING USEFUL PEPTIDES
 TIFR PROCEDURE DE PRODUCTION ET DE SEPARATION DE PEPTIDES UTILES
 IN VENTON, Duane, L.;
 HOPFINGER, Anton, J.;
 LE BRETON, Guy
 RECEPTOR LABORATORIES, INC.;
 VENTON, Duane, L.;
 HOPFINGER, Anton, J.;
 LE BRETON, Guy
 English
 DT Patent
 PI WO 9304079 A1 19930304
 DS W: AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KR LK LU MG
 MN NM NL NO PL RO RU SD SE US AT BE CH DE DK ES FR GB GR IE
 IT LU MC NL SE BR BG CF CG CI CM GA GN HL MR SN TD TG
 AI WO 1992-US6933 A 19920820
 PRAI US 1991-813, 315 19910821
 ICM C07K001-12
 C07K003-10; C12P021-06; B01D061-14; G01N033-68
 L9 ANSWER 41 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
 AN 1992021344 PCTFULL. ED 20020513
 TIEN MODULATION OF CELLULAR RESPONSE TO EXTERNAL STIMULI
 TIFR MODULATION DE LA REPONSE CELLULAIRE A DES STIMULI EXTERNES
 IN BIANCO, James, A.;
 BURSTEN, Stuart, L.;
 SINGER, Jack, W.
 FRED HUTCHINSON CANCER RESEARCH CENTER;
 BIANCO, James, A.;
 BURSTEN, Stuart, L.;
 SINGER, Jack, W.
 English
 DT Patent
 PI WO 9221344 A2 19921210
 DS W: AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KR LK LU MG
 DK ES FI FR GA GB GN GR HU IT JP KR LK LU LU MC MG
 ML MN MR NM NL NO PL RO RU SD SE SN TD TG US
 AI WO 1992-US4349 A 19920522
 PRAI US 1991-704, 992 19910524
 ICM US 1991-732, 227 19910716
 A61K031-52
 L9 ANSWER 42 OF 42 PCTFULL. COPYRIGHT 2003 Univentio
 AN 1992007083 PCTFULL. ED 20020513
 TIEN ANTIBODIES AGAINST THE UROKINASE RECEPTOR AND THEIR USE
 TIFR ANTICORPS CONTRE LE RECEPTEUR DE L'UROKINASE ET LEUR UTILISATION
 IN DANO, Keld;
 RONNE, Ebbe;
 BREHENDT, Niels;
 ELLIS, Vincent;
 HOYER-HANSEN, Gunilla;
 PYKE, Charles;
 BRUENNER, Nils
 CANCERFORSKNINGSFONDET AF 1989;
 DANO, Keld;
 RONNE, Ebbe;

BEHRENDT, Niels;
 ELLIS, Vincent;
 HOYER-HANSEN, Gunilla;
 PYKE, Charles;
 BRUENNER, Nils
 English
 Patent
 WO 9207083
 W: AT AU BE CA CH DE DK ES FI FR GB GR HU IT JP KR LU NL NO SE
 SU US
 A1 19920430
 WO 1991-DK319 A 19911018
 PRAI US 1990-PCT/DK90/00270 19901018
 ICM CL2P021-08
 ICS A61K039-395; A61K031-185; G01N033-68

=> d ab 32

L9 ANSWER 32 OF 42 PCTFULL COPYRIGHT 2003 Univentio
 ABEN The invention relates to methods for identifying prostatic
 intraepithelial neoplasia, methods
 for determining metastatic potential of tumors, and to methods and
 compositions for inhibiting or
 preventing metastasis of cancers. In one aspect, the invention provides
 a method to determine
 metastatic potential of tumors, particularly prostatic tumors. In
 another aspect, the invention
 provides a method of identifying prostate cancer associated conditions,
 particularly prostatic
 intraepithelial neoplasia. In these regards, the invention
 relates to determining protein or mRNA of
 effectors of arachidonic acid release, particularly uteroglobin protein
 or mRNA, to identify
 intermediate conditions such as PIN or to gauge metastatic potential of
 prostatic tumors. The
 invention also relates to methods and compositions that prevent or
 inhibit metastasis of cancers. In
 this regard, the invention particularly relates to methods and
 compositions that inhibit arachidonic
 acid, those that inhibit phospholipase A2. More particularly in this
 regard, the invention relates
 to uteroglobin or muteins, peptide analogs or mimetics of uteroglobin
 and lipocortins or muteins,
 peptidic analogs, or mimetics of lipocortins that inhibit metastasis.
 Especially it relates to
 methods and compositions in which uteroglobins, particularly human
 uteroglobins, inhibit or prevent
 metastasis of cancer, particularly prostatic cancer.
 L'invention concerne des procedes d'identification de la neoplasie
 intra-epitheliale
 prostaticque, des procedes de determination du potentiel metastatique de
 tumeurs, ainsi que des
 procedes et des compositions destines a inhiber ou prevenir les
 metastases de cancers. Dans un
 aspect de l'invention, on decrit un procede de determination du
 potentiel metastatique de tumeurs. Dans un autre aspect de l'invention,
 notamment de tumeurs prostaticques. Dans un autre aspect de l'invention,
 on decrit un procede
 d'identification de conditions associees au cancer de la prostate,
 notamment la neoplasie
 intra-epitheliale prostaticque. A cet egard, l'invention se rapporte a
 une determination de la
 proteine ou de l'ARNm d'effecteurs de la liberation de l'acide
 arachidonique, notamment la proteine
 uteroglobine ou l'ARNm, afin d'identifier des conditions intermediaires

telles que la neoplasie
 intra-epitheliale prostaticque, ou afin d'evaluer le potentiel
 metastatique de tumeurs de la
 prostate. L'invention concerne encore des procedes et compositions qui
 previennent ou inhibent les
 metastases des cancers. A cet egard, l'invention concerne notamment des
 procedes et compositions qui
 inhibent l'acide arachidonique ainsi que la phospholipase A2.
 L'invention se rapporte plus
 particulierement a l'uteroglobine ou aux muteins, aux analogues
 peptidiques ou aux mimetiques de
 l'uteroglobine, et aux lipocortins, ou aux muteins, aux analogues
 peptidiques ou aux mimetiques
 des lipocortins qui inhibent les metastases, et elle se rapporte
 specialement aux procedes et
 compositions dans lesquels les uteroglobines, notamment les
 uteroglobines humaines, inhibent ou
 previennent les metastases du cancer et particulierement celles du
 cancer de la prostate.

=>

---Logging off of STN---

=>
 Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	87.57	87.78
STN INTERNATIONAL LOGOFF AT 18:10:35 ON 11 MAR 2003		